Engineering dendritic cell vaccines to improve cancer immunotherapy

At the interface between the innate and adaptive immune system, dendritic cells (DCs) play key roles in tumour immunity and hold a hitherto unrealized potential for cancer immunotherapy. Here we review the role of distinct DC subsets in the tumour microenvironment, with special emphasis on conventio...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Caleb R., De Palma, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881351/
https://www.ncbi.nlm.nih.gov/pubmed/31776331
http://dx.doi.org/10.1038/s41467-019-13368-y
_version_ 1783473928460566528
author Perez, Caleb R.
De Palma, Michele
author_facet Perez, Caleb R.
De Palma, Michele
author_sort Perez, Caleb R.
collection PubMed
description At the interface between the innate and adaptive immune system, dendritic cells (DCs) play key roles in tumour immunity and hold a hitherto unrealized potential for cancer immunotherapy. Here we review the role of distinct DC subsets in the tumour microenvironment, with special emphasis on conventional type 1 DCs. Integrating new knowledge of DC biology and advancements in cell engineering, we provide a blueprint for the rational design of optimized DC vaccines for personalized cancer medicine.
format Online
Article
Text
id pubmed-6881351
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-68813512019-11-29 Engineering dendritic cell vaccines to improve cancer immunotherapy Perez, Caleb R. De Palma, Michele Nat Commun Perspective At the interface between the innate and adaptive immune system, dendritic cells (DCs) play key roles in tumour immunity and hold a hitherto unrealized potential for cancer immunotherapy. Here we review the role of distinct DC subsets in the tumour microenvironment, with special emphasis on conventional type 1 DCs. Integrating new knowledge of DC biology and advancements in cell engineering, we provide a blueprint for the rational design of optimized DC vaccines for personalized cancer medicine. Nature Publishing Group UK 2019-11-27 /pmc/articles/PMC6881351/ /pubmed/31776331 http://dx.doi.org/10.1038/s41467-019-13368-y Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Perspective
Perez, Caleb R.
De Palma, Michele
Engineering dendritic cell vaccines to improve cancer immunotherapy
title Engineering dendritic cell vaccines to improve cancer immunotherapy
title_full Engineering dendritic cell vaccines to improve cancer immunotherapy
title_fullStr Engineering dendritic cell vaccines to improve cancer immunotherapy
title_full_unstemmed Engineering dendritic cell vaccines to improve cancer immunotherapy
title_short Engineering dendritic cell vaccines to improve cancer immunotherapy
title_sort engineering dendritic cell vaccines to improve cancer immunotherapy
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881351/
https://www.ncbi.nlm.nih.gov/pubmed/31776331
http://dx.doi.org/10.1038/s41467-019-13368-y
work_keys_str_mv AT perezcalebr engineeringdendriticcellvaccinestoimprovecancerimmunotherapy
AT depalmamichele engineeringdendriticcellvaccinestoimprovecancerimmunotherapy

Ejemplares similares